Trastuzumab Deruxtecan 100MG Injection is a targeted oncology medicine used for selected HER2-related cancers. It is an antibody-drug conjugate (ADC) that combines HER2-targeting therapy with a cytotoxic payload.
Cordium Pharmaceuticals Pvt Ltd is an India-based pharmaceutical exporter providing international supply support for eligible hospitals, oncology centers, pharmaceutical distributors and authorized buyers.
Trastuzumab Deruxtecan 100MG Injection Supply
Cordium Pharmaceuticals Pvt Ltd accepts inquiries for Trastuzumab Deruxtecan 100MG Injection for eligible buyers in:
USA
UK
UAE
South Africa
Supply and importation are subject to destination-country regulations.
Uses
Depending on the approved indication, Trastuzumab Deruxtecan may be used for selected:
HER2-positive breast cancer
HER2-low or HER2-ultralow breast cancer
HER2-mutant non-small cell lung cancer
HER2-positive gastric or gastroesophageal junction cancer
Certain other HER2-positive solid tumors
Dosage & Administration
The 100MG is the vial strength, not necessarily the patient's prescribed dose.
For several indications, the recommended dose is 5.4 mg/kg IV every 3 weeks, while certain gastric/GEJ indications use 6.4 mg/kg every 3 weeks.
It must be administered by qualified healthcare professionals.
Benefits
HER2-targeted cancer therapy
Antibody-drug conjugate technology
Used for multiple approved HER2-related cancers
Treatment option for selected advanced or metastatic cancers
Side Effects & Safety
Possible side effects include nausea, vomiting, fatigue, decreased appetite, low blood-cell counts, anemia, hair loss and gastrointestinal symptoms.
Important serious risks include interstitial lung disease/pneumonitis, neutropenia and cardiac dysfunction. Patients should promptly report breathing problems, persistent fever or other serious symptoms.
Why Choose Cordium Pharmaceuticals?
India-based pharmaceutical exporter
International supply support
Hospital and distributor order coordination
Export documentation assistance
Professional shipment coordination
Support for eligible international pharmaceutical buyers
USA, UK, UAE & South Africa
Cordium Pharmaceuticals supports export inquiries for eligible buyers in the USA, UK, UAE and South Africa. Buyers should verify local registration, prescription and import requirements before procurement.
FAQs
What is Trastuzumab Deruxtecan 100MG?
A HER2-targeted antibody-drug conjugate used for selected cancers.
Is 100MG the patient dose?
No. It is the vial strength. The prescribed dose depends on the indication and patient characteristics.
How often is it administered?
Many approved indications use treatment every three weeks.
Can it be self-administered?
No. It requires intravenous administration by trained healthcare professionals.
Who can purchase it?
Eligible hospitals, oncology centers, authorized distributors and pharmaceutical buyers, subject to local regulations.
Conclusion
Trastuzumab Deruxtecan 100MG Injection is an important targeted oncology medicine for selected HER2-related cancers. Cordium Pharmaceuticals Pvt Ltd provides pharmaceutical export support from India for eligible buyers in the USA, UK, UAE and South Africa.
Medical Disclaimer: This content is for informational purposes only. Use of trastuzumab deruxtecan requires a qualified healthcare professional's prescription and supervision.
Cordium Pharmaceuticals Pvt Ltd is an India-based pharmaceutical exporter providing international supply support for eligible hospitals, oncology centers, pharmaceutical distributors and authorized buyers.
Trastuzumab Deruxtecan 100MG Injection Supply
Cordium Pharmaceuticals Pvt Ltd accepts inquiries for Trastuzumab Deruxtecan 100MG Injection for eligible buyers in:
USA
UK
UAE
South Africa
Supply and importation are subject to destination-country regulations.
Uses
Depending on the approved indication, Trastuzumab Deruxtecan may be used for selected:
HER2-positive breast cancer
HER2-low or HER2-ultralow breast cancer
HER2-mutant non-small cell lung cancer
HER2-positive gastric or gastroesophageal junction cancer
Certain other HER2-positive solid tumors
Dosage & Administration
The 100MG is the vial strength, not necessarily the patient's prescribed dose.
For several indications, the recommended dose is 5.4 mg/kg IV every 3 weeks, while certain gastric/GEJ indications use 6.4 mg/kg every 3 weeks.
It must be administered by qualified healthcare professionals.
Benefits
HER2-targeted cancer therapy
Antibody-drug conjugate technology
Used for multiple approved HER2-related cancers
Treatment option for selected advanced or metastatic cancers
Side Effects & Safety
Possible side effects include nausea, vomiting, fatigue, decreased appetite, low blood-cell counts, anemia, hair loss and gastrointestinal symptoms.
Important serious risks include interstitial lung disease/pneumonitis, neutropenia and cardiac dysfunction. Patients should promptly report breathing problems, persistent fever or other serious symptoms.
Why Choose Cordium Pharmaceuticals?
India-based pharmaceutical exporter
International supply support
Hospital and distributor order coordination
Export documentation assistance
Professional shipment coordination
Support for eligible international pharmaceutical buyers
USA, UK, UAE & South Africa
Cordium Pharmaceuticals supports export inquiries for eligible buyers in the USA, UK, UAE and South Africa. Buyers should verify local registration, prescription and import requirements before procurement.
FAQs
What is Trastuzumab Deruxtecan 100MG?
A HER2-targeted antibody-drug conjugate used for selected cancers.
Is 100MG the patient dose?
No. It is the vial strength. The prescribed dose depends on the indication and patient characteristics.
How often is it administered?
Many approved indications use treatment every three weeks.
Can it be self-administered?
No. It requires intravenous administration by trained healthcare professionals.
Who can purchase it?
Eligible hospitals, oncology centers, authorized distributors and pharmaceutical buyers, subject to local regulations.
Conclusion
Trastuzumab Deruxtecan 100MG Injection is an important targeted oncology medicine for selected HER2-related cancers. Cordium Pharmaceuticals Pvt Ltd provides pharmaceutical export support from India for eligible buyers in the USA, UK, UAE and South Africa.
Medical Disclaimer: This content is for informational purposes only. Use of trastuzumab deruxtecan requires a qualified healthcare professional's prescription and supervision.
Keywords
